Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 151

Sort by

Sort Order Select

Journal Articles

Clinical characteristics and comutational landscape of CSF3R mutations in acute myeloid leukemia

Lara Wiechers, Rabea Mecklenbrauck, Razif Gabdoulline, Henri C. Hupe, Piroska Poll, Rabia Shahswar, Franziska Westendorf, Walter Fiedler, Arnold Ganser, Florian Heidel, Michael Heuser, Felicitas R Thol

Blood (2025) 146 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2025-1718

Published: 2025

Journal Articles

A diagnostic pitfall: Therapy-related acute promyelocytic leukemia mimicking mixed-phenotype acute leukemia

Elisa Seubert, Felix Ullrich, Moritz Kruppa, Lukas Küster, Christoph Schaefers, Felix Klingler, Carsten Bokemeyer, Walter Fiedler, Thomas Stübig, Franziska Westendorf

Blood (2025) 146 (Supplement 1): 6936.

https://doi.org/10.1182/blood-2025-6936

Published: 2025

Journal Articles

Osteonecrosis risk in adult ALL: Insights from real-world clinical laboratory data in eighty-seven patients treated with peg-asparaginase

Felix Klingler, Nicola Gökbuget, Carsten Bokemeyer, Walter Fiedler, Franziska Westendorf

Blood (2025) 146 (Supplement 1): 3322.

https://doi.org/10.1182/blood-2025-3322

Published: 2025

Journal Articles

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

Blood (2025) 146 (Supplement 1): 1640.

https://doi.org/10.1182/blood-2025-1640

Published: 2025

Journal Articles

Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry

Blood (2025) 146 (Supplement 1): 5124.

https://doi.org/10.1182/blood-2025-5124

Published: 2025

Journal Articles

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Heike Pfeifer, Fabian Lang, Walter Fiedler, Matthias Stelljes, Folker Schneller, Björn Steffen, Boris Böll, Andreas Viardot, Christoph Faul, Lino L. Teichmann, Hendrik Poeck, Joerg Westermann, Kerstin Schäfer-Eckart, Thomas Heinicke, Thomas Burmeister, Stefan Schwartz, Monika Brueggemann, Hubert Serve, Nicola Goekbuget

Blood (2024) 144 (Supplement 1): 840.

https://doi.org/10.1182/blood-2024-201217

Published: 2024

Journal Articles

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Blood (2024) 144 (Supplement 1): 631.

https://doi.org/10.1182/blood-2024-199601

Published: 2024

Journal Articles

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

Anjali Cremer, Maher Hanoun, Ralph Wäsch, Simon Raffel, Klaus Wethmar, Andreas Viardot, Walter Fiedler, Knut Wendelin, Lore Marretta, Wolfram Jung, Roland Schroers, Vladan Vucinic, Monika Brüggemann, Stefan Schwartz, Hubert Serve, Nicola Goekbuget

Blood (2024) 144 (Supplement 1): 1436.

https://doi.org/10.1182/blood-2024-202270

Published: 2024

Journal Articles

CD39 Is Predominantly Expressed in Adverse AML Patients and Blockade By a New Anti-CD39 Nanobody Increases Lysis of AML Blasts

Franziska Brauneck, Stefan Menzel, Niklas Kruppa, Fritz Koch-Nolte, Walter Fiedler, Jasmin Wellbrock

Blood (2024) 144 (Supplement 1): 1397.

https://doi.org/10.1182/blood-2024-206914

Published: 2024

Journal Articles

The PTPN2/PTPN1 Inhibitor Abbv-CLS-484 Augments Immune Responses Against Leukemic Blasts and Impedes Leukemia Cell Proliferation in AML Alone and in Combination with Venetoclax

Niklas Kruppa, Moritz Kruppa, Jana Muschhammer, Nadine Felber, Franziska Brauneck, Franziska Modemann, Jasmin Wellbrock, Walter Fiedler

Blood (2024) 144 (Supplement 1): 1374.

https://doi.org/10.1182/blood-2024-201504

Published: 2024

Journal Articles

Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 737.

https://doi.org/10.1182/blood-2024-207953

Published: 2024

Journal Articles

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Blood (2024) 144 (Supplement 1): 961.

https://doi.org/10.1182/blood-2024-199060

Published: 2024

Journal Articles

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Blood (2024) 143 (14): 1391–1398.

https://doi.org/10.1182/blood.2023021752

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Impact of Clonality of Myelodysplasia-Related Gene Mutations in AML

Rabea Mecklenbrauck, Nora Borchert, Piroska Klement, Carolin Funke, Maximilian Brandes, Louisa-Kristin Dallmann, Walter Fiedler, Jürgen Krauter, Arne Trummer, Bernd Hertenstein, Verena I. Gaidzik, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Felicitas Thol, Michael Heuser

Blood (2023) 142 (Supplement 1): 817.

https://doi.org/10.1182/blood-2023-179412

Published: 2023

Journal Articles

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Kumaran Nagarajan, Britta Steer, Philipp Nakov, Björn Steffen, Dorothee Deckbar, Sonja Bendig, Lorenz Bastian, Martin Neumann, Monika Brueggemann, Nicola Goekbuget, Claudia D Baldus

Blood (2023) 142 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2023-173937

Published: 2023

Journal Articles

The Genomic Landscape and Its Clinical Implication in NPM1 -Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial

Blood (2023) 142 (Supplement 1): 4311.

https://doi.org/10.1182/blood-2023-185566

Published: 2023

Journal Articles

Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

Blood (2023) 142 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2023-181833

Published: 2023

Journal Articles

Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML

Martin Wermke, Stephan Metzelder, Sabrina Kraus, Elisa Sala, Vladan Vucinic, Walter Fiedler, Katrin Wetzko, Jonas Schäfer, Maria-Elisabeth Goebeler, Jan Koedam, Kristin Franke, Matti Vänskä, Armin Ehninger, Marc Cartellieri, Gerhard Ehninger, Tapan Maniar

Blood (2023) 142 (Supplement 1): 3465.

https://doi.org/10.1182/blood-2023-177867

Published: 2023

Journal Articles

Loss of SMARCA4 Leads to an Impaired Hematopoiesis in Mice

Franziska Modemann, Leoni Ramke, Erkin Erdal, Melanie Schoof, Carolin Göbel, Sina Neyazi, Carsten Bokemeyer, Jasmin Wellbrock, Ulrich Schüller, Walter Fiedler

Blood (2023) 142 (Supplement 1): 1377.

https://doi.org/10.1182/blood-2023-178137

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical characteristics and comutational landscape of CSF3R mutations in acute myeloid leukemia

A diagnostic pitfall: Therapy-related acute promyelocytic leukemia mimicking mixed-phenotype acute leukemia

Osteonecrosis risk in adult ALL: Insights from real-world clinical laboratory data in eighty-seven patients treated with peg-asparaginase

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

CD39 Is Predominantly Expressed in Adverse AML Patients and Blockade By a New Anti-CD39 Nanobody Increases Lysis of AML Blasts

The PTPN2/PTPN1 Inhibitor Abbv-CLS-484 Augments Immune Responses Against Leukemic Blasts and Impedes Leukemia Cell Proliferation in AML Alone and in Combination with Venetoclax

Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Prognostic Impact of Clonality of Myelodysplasia-Related Gene Mutations in AML

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

The Genomic Landscape and Its Clinical Implication in NPM1 -Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial

Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML

Loss of SMARCA4 Leads to an Impaired Hematopoiesis in Mice

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only